Algert Global LLC Buys Shares of 21,401 Zoetis Inc (ZTS)

Algert Global LLC bought a new stake in shares of Zoetis Inc (NYSE:ZTS) in the third quarter, HoldingsChannel reports. The fund bought 21,401 shares of the company’s stock, valued at approximately $1,959,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC boosted its holdings in shares of Zoetis by 34.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after buying an additional 566 shares in the last quarter. Rehmann Capital Advisory Group boosted its holdings in shares of Zoetis by 40.5% during the 2nd quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock worth $187,000 after buying an additional 631 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Zoetis by 23.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,746 shares of the company’s stock worth $319,000 after buying an additional 700 shares in the last quarter. Chesley Taft & Associates LLC boosted its holdings in shares of Zoetis by 3.0% during the 3rd quarter. Chesley Taft & Associates LLC now owns 23,770 shares of the company’s stock worth $2,176,000 after buying an additional 700 shares in the last quarter. Finally, S&CO Inc. boosted its holdings in shares of Zoetis by 6.0% during the 3rd quarter. S&CO Inc. now owns 12,447 shares of the company’s stock worth $1,140,000 after buying an additional 700 shares in the last quarter. 89.94% of the stock is owned by institutional investors and hedge funds.

Shares of ZTS opened at $90.41 on Friday. Zoetis Inc has a 12-month low of $70.20 and a 12-month high of $96.57. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04. The firm has a market capitalization of $43.51 billion, a P/E ratio of 37.67, a PEG ratio of 1.79 and a beta of 0.99.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The company had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same period last year, the business earned $0.65 EPS. Zoetis’s quarterly revenue was up 9.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc will post 3.11 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Tuesday, November 20th were issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Monday, November 19th. Zoetis’s dividend payout ratio is currently 20.83%.

In other Zoetis news, Director Willie M. Reed sold 3,205 shares of the firm’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $93.74, for a total transaction of $300,436.70. Following the transaction, the director now directly owns 566 shares in the company, valued at approximately $53,056.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $92.03, for a total value of $184,060.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 169,511 shares of company stock worth $16,081,299. 0.35% of the stock is owned by company insiders.

A number of research firms have issued reports on ZTS. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, October 17th. Morgan Stanley set a $100.00 price target on Zoetis and gave the stock a “hold” rating in a report on Friday, November 2nd. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Argus increased their target price on Zoetis from $90.00 to $103.00 and gave the stock a “buy” rating in a report on Tuesday, August 14th. Finally, BMO Capital Markets increased their target price on Zoetis to $93.00 and gave the stock a “neutral” rating in a report on Monday, November 12th. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $94.00.

ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Buys Shares of 21,401 Zoetis Inc (ZTS)” was published by WKRB News and is owned by of WKRB News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.wkrb13.com/2018/12/07/algert-global-llc-buys-shares-of-21401-zoetis-inc-zts.html.

About Zoetis

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Recommended Story: Terms to Better Understand Call Options

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply